Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia

Crinetics will host an investor conference call on January 10, 2025, at 8:30 am Eastern Time to discuss the positive topline results from an open-label, Phase 2 congenital adrenal hyperplasia (CAH) study of atumelnant.

Dial-in Details:
Domestic: 1-800-445-7795
International: 1-785-424-1699
Conference ID: CRNXQ4